Ori Biotech
Makes IRO, an automated closed-system platform for manufacturing cell and gene therapies from R&D through commercial production.
oribiotech.com ↗Why it's here
Signed a 10-year commercial agreement worth up to $120M to move an approved cell therapy onto its IRO platform, announced September 2026.
source: pharmamanufacturing.com- Focus
- Cell therapy manufacturing
- Founded
- 2015
- Latest round
- Series B, $100M+, Jan 2022
- London office
- MAYDE, 5-10 Brandon Road, London N7 9AA, Islington N7 9AAsource: oribiotech.com
- London presence
- HQsource: oribiotech.com
- Investors
- Novalis LifeSciences (lead), Amadeus Capital Partners, Chimera Abu Dhabi, Delin Ventures, Northpond Ventures, Octopus Ventures, Puhua Capitalsource: life-sciences-europe.com
- Area
- King's Cross
- Nearest station
- Caledonian Road & Barnsbury, 563 m
- Companies House
- ORIBIOTECH LTD (09757696, active)Incorporated 2 Sep 2015 · SIC 71121, 71200, 72110, 72190
- Visas
- Licensed visa sponsor, listed as OriBiotech Ltdsource: gov.uk
- Elsewhere
- LinkedIn ↗
Verified 8 Oct 2026. How we verify · Suggest a fix
For Ori Biotech
Work here? Show you're on the map. Add the badge to your site or README, or share the listing.
<a href="https://londonmempool.co.uk/c/ori-biotech"><img src="https://londonmempool.co.uk/badge/ori-biotech.svg" alt="Ori Biotech is listed on London Mempool" width="357" height="28"></a>
Add ?theme=light to the image URL for light backgrounds.